Michael McLean Appointed as Chairman of Link Technologies Ltd

14-May-2007

Link Technologies Limited, manufacturer of oligonucleotide synthesis reagents, has appointed former President of Avecia Biotechnology Inc, Dr Michael McLean, as Chairman to lead them through an exciting period of change and expansion. The Company is actively seeking business partners to co-develop new products and commercialise and licence new research technologies.

Dr McLean, currently CEO of Oligovax (France), said: "We welcome approaches from interested parties to discuss opportunities. Our chemistry expertise is a perfect match for life science companies working in diverse areas such as molecular diagnostics, microarrays and therapeutics".

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures